Evidence map›Paper›PMID 41008281›Full record

ArticleBrain sciences2025

Causes of Death in Anti-IgLON5 Disease: A Novel Case Report and Systematic Literature Review.

Tina Howischer, Lukas Gattermeyer-Kell, Stephanie Hirschbichler, Thomas Seifert-Held, Jan Hinrich Bräsen, Petra Katschnig-Winter, Mariella Kögl, Sebastian Franthal, Christian Enzinger, Romana Höftberger and 1 more

Abstract readCase Reports
In one paragraph

Article in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tina HowischerDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.
Lukas Gattermeyer-KellDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.ORCID 0009-0009-9699-2959
Stephanie HirschbichlerDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-9554-4275
Thomas Seifert-HeldDepartment of Neurology, Hospital Murtal, 8720 Knittelfeld, Austria.
Jan Hinrich BräsenDepartment of Pathology, University of Hannover, 30625 Hannover, Germany.ORCID 0000-0002-2863-3067
Petra Katschnig-WinterDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.
Mariella KöglDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.ORCID 0009-0002-5769-6195
Sebastian FranthalDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0001-7147-9037
Christian EnzingerDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.
Romana HöftbergerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1097 Vienna, Austria.
Petra SchwingenschuhDepartment of Neurology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-3294-6824

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesAnti-IgLON5 disease is a neurological disorder characterized by the presence of autoantibodies directed against the neuronal cell adhesion protein IgLON5. Pathophysiology involves both autoimmune inflammation and neurodegenerative processes. The most common causes of death are sudden death, central hypoventilation, dysphagia, and aspiration. However, the high rate of largely unclear sudden deaths calls for further research in this area.

methodsWe performed a systematic search of the literature on causes of death in anti-IgLON5 disease following the PRISMA guidelines. In addition, we present a new case that was followed up in our clinic until death.

resultsOf 258 publications with anti-IgLON5 disease, 21 publications comprising 61 cases that reported the causes of death were included in the analysis. The most common cause of death was death due to complications at 36.1%, followed by sudden death, accounting for 32.8% of the cases. Other causes include respiratory, cardiac, and unknown causes. The patient presented here as a case report was also diagnosed with cardiac amyloidosis and died from a cardiac cause of sudden death.

conclusionsSudden death in anti-IgLON5 disease is one of the most common causes of death in the literature. A progressive neurodegenerative process in the brain stem causing central hypoventilation is generally assumed as a major causative factor. The case reported here had concomitant cardiac amyloidosis, which may raise the question as to whether unrecognized cardiac causes, which are not routinely screened for in this population, might represent another cause of sudden death, which would have important therapeutic implications.

Indexed as

anti-IgLON5 diseaseATTR amyloidosiscase reportcauses of deathsudden deathsystematic reviewtransthyretin amyloidosis

Identifiers

PMID41008281
PMCPMC12467548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.